Please assess the completion status of the following clinical trial:

Trial Title: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 or older~* The CHB patients (both HBeAg-positive and - negative) who have at least 6 months undetectable HBV DNA (serum HBV DNA ≤ 20 IU/mL) after lamivudine plus adefovir combination therapy.~Exclusion Criteria:~* Patients with decompensated liver disease~* Patients with HCV, HDV or HIV~* Patients with HCC~* Serum ALT \> 2x ULN level~* Serum creatinine \> 2.0mg/dL~* Pregnant or lactating women~* Women who have a plan for pregnancy within the three coming years~* Patients who have uncontrolled severe concomitant diseases- severe cardiovascular diseases and other infection~* Those who have no capabilities to understand and sign an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamivudine plus adefovir (Type: ACTIVE_COMPARATOR): Continue lamivudine/adefovir add on treatment (standard treatment)
- Tenofovir (Type: EXPERIMENTAL): Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).